See the Whole Landscape Shape What's Next in Pharma
GBI Health unites global pharmaceutical data, AI capabilities and industry expertise to deliver future-ready solutions across the entire product lifecycle.
Products
GBI Health Data Intelligence Suite
Solutions
Full Life-Cycle Solutions for Pharmaceuticals
Powered by global drug pipeline data, the Competitive Landscape Analysis solution enables multidimensional analysis across drugs, targets, indications, and technologies. It helps R&D teams identify strategic opportunities, prioritize investments, and make more informed development decisions.
Drawing on data from six major global clinical trial registries, the Clinical R&D Insights solution provides deep visibility into global trial activity and protocol designs, helping teams optimize clinical development strategies and trial execution.
Drawing on data covering the National Reimbursement Drug List (NRDL), public procurement and tendering, Huiminbao (commercial health insurance), Patient Assistance Programs (PAPs), and healthcare policies and regulations, the Market Access Strategy solution supports market access planning, pricing analysis, and regional opportunity assessment to accelerate commercialization and market access.
Built on comprehensive researcher profiles, the GBI KOL/HCP Management solution enables researcher identification, segmentation, academic influence analysis, and collaboration network mapping, helping Medical Affairs, Marketing, and Sales teams improve researcher engagement and operational efficiency.
Industry News and Reports
Aggregating industry news and in-depth reports to help pharma companies stay ahead.
- GSK’s PD-1 Jemperli accepted for priority review by FDA for dMMR/MSI-H rectal cancer
On August 24, GSK (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) for patients with previously untreated stage II and III mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) locally advanced rectal cancer.
- Haisco enters into preclinical autoimmune project licensing agreement with Sentivera
On August 26, 2026, Haisco (002653.SZ) announced that it has signed an exclusive licensing agreement with U.S.-based Sentivera Therapeutics, Inc. (formerly RespiveraHealths, Inc.), granting Sentivera exclusive rights to develop, manufacture, and commercialize a preclinical autoimmune asset worldwide, excluding Mainland China, Hong Kong, Macau, and Taiwan.
- Gilead’s Trodelvy plus MSD’s Keytruda nodded for 1st-line TNBC in EU
On August 24, Gilead Sciences (Nasdaq: GILD) announced that the European Commission (EC) has granted marketing authorization for Trop-2 ADC Trodelvy (sacituzumab govitecan-hziy) in combination with MSD’s PD-1 antibody Keytruda (pembrolizumab) for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumors express PD-L1 with a combined positive score (CPS ≥10).
- Takeda China partners with Ant Group
On August 25, 2026, Takeda China entered into a partnership agreement with Ant Group. Combining Takeda's expertise and medical insights in key disease areas with Ant Group's strengths in artificial intelligence (AI), digital platforms, and ecosystem connectivity, the two parties will collaborate around patient needs and healthcare service scenarios.
- Fosun Pharma recorded revenue of RMB 20.442b in 2026H1
On August 25, Fosun Pharma (600196.SH; 02196.HK) announced its interim results for 2026.
- WuXi Biologics' H1 2026 revenue up 18.4%
On August 25, 2026, WuXi Biologics (2269.HK) announced its interim results for the six months ended June 30, 2026.
In-Depth, Exclusive Industry Reports
Curated by expert analysts, offering in-depth analysis of emerging industry trends and the competitive landscape.
Scan the QR code to follow the GBIHealth WeChat Official Account for industry news, live webinars, thematic reports, and more.
Reliable partner for 95%+ key global medical industry players
Our clients are drawn from across pharma, medical device firms, CROs/CDMOs, investors, consulting firms, and others
See the Whole Landscape Shape What's Next in Pharma
GBI Health unites global pharmaceutical data, AI capabilities and industry expertise to deliver future-ready solutions across the entire product lifecycle.
Contact Us